胰腺癌：转移性疾病的治疗试验。
Pancreas cancer: Therapeutic trials in metastatic disease.
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
出版信息
J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
Abstract
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.
摘要
转移性胰腺导管腺癌 (PDAC) 是 2021 年癌症相关死亡的主要原因。细胞毒性疗法是 PDAC 的主要治疗方法。奥拉帕利作为种系 BRCA1/2 突变 PDAC 的维持治疗以及帕博利珠单抗作为错配修复缺陷 PDAC 的治疗药物的最近获批代表了该疾病的分子靶向治疗方法。研究性治疗策略包括针对基质、代谢、肿瘤微环境和免疫系统，本文回顾了一些选定的方法。
相似文献
1
Pancreas cancer: Therapeutic trials in metastatic disease.胰腺癌：转移性疾病的治疗试验。
J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
2
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.转移性胰腺导管腺癌的新治疗策略。
Drugs. 2020 May;80(7):647-669. doi: 10.1007/s40265-020-01304-0.
3
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.在胰腺导管腺癌中向个体化治疗的演变：挑战与机遇。
Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. doi: 10.1080/14737140.2018.1417844. Epub 2017 Dec 19.
4
Perspectives in the treatment of pancreatic adenocarcinoma.胰腺腺癌的治疗前景
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
5
Emerging Treatment Strategies in Pancreatic Cancer.胰腺癌的新兴治疗策略
Pancreas. 2021 Jul 1;50(6):773-787. doi: 10.1097/MPA.0000000000001845.
6
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.胰腺癌的局部和全身免疫抑制：靶向肿瘤武器库中的中坚力量。
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188387. doi: 10.1016/j.bbcan.2020.188387. Epub 2020 Jun 21.
7
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.胰腺导管腺癌的分子改变与靶向治疗。
J Hematol Oncol. 2020 Oct 2;13(1):130. doi: 10.1186/s13045-020-00958-3.
8
Novel Therapeutics for Pancreatic Adenocarcinoma.胰腺癌的新型治疗方法
Hematol Oncol Clin North Am. 2015 Aug;29(4):777-87. doi: 10.1016/j.hoc.2015.04.006.
9
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.胰腺导管腺癌：当前及不断发展的治疗方法
Int J Mol Sci. 2017 Jun 22;18(7):1338. doi: 10.3390/ijms18071338.
10
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.可切除胰腺导管腺癌的多模式治疗。
Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4.
引用本文的文献
1
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.脂质体伊立替康在转移性胰腺癌一线治疗中的整合：试着不要去想白熊。
Ther Adv Med Oncol. 2024 Apr 4;16:17588359241234487. doi: 10.1177/17588359241234487. eCollection 2024.
2
The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells.蛋白磷酸酶-2A 亚基 PR130 参与了胰腺导管腺癌细胞中细胞毒性蛋白聚集体的形成。
Cell Commun Signal. 2024 Apr 3;22(1):217. doi: 10.1186/s12964-024-01597-8.
3
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.胰腺癌致癌途径的临床及临床前靶向治疗：针对最致命癌症的靶向治疗方法
Int J Mol Sci. 2024 Mar 1;25(5):2860. doi: 10.3390/ijms25052860.
4
Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma.围手术期溶瘤病毒疗法可对抗手术引起的免疫抑制并改善胰腺导管腺癌的治疗效果。
Front Oncol. 2023 Feb 16;13:1071751. doi: 10.3389/fonc.2023.1071751. eCollection 2023.
5
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.表观遗传药物筛选定义了一种对 PRMT5 抑制剂敏感的胰腺癌亚型。
JCI Insight. 2022 May 23;7(10):e151353. doi: 10.1172/jci.insight.151353.
6
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.解读CHFR在胰腺导管腺癌中的作用
Front Med (Lausanne). 2021 Nov 19;8:720128. doi: 10.3389/fmed.2021.720128. eCollection 2021.
7
Rationale for MYC imaging and targeting in pancreatic cancer.胰腺癌中MYC成像与靶向治疗的原理。
EJNMMI Res. 2021 Oct 12;11(1):104. doi: 10.1186/s13550-021-00843-1.
8
[F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.[F]氟代脱氧葡萄糖正电子发射断层扫描/磁共振成像（FDG PET/MRI）能够对胰腺导管腺癌的早期化疗反应进行预测。
EJNMMI Res. 2021 Jul 28;11(1):70. doi: 10.1186/s13550-021-00808-4.
9
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.肿瘤突变负荷作为胰腺癌免疫治疗的潜在生物标志物：系统评价与仍未解决的问题
Cancers (Basel). 2021 Jun 22;13(13):3119. doi: 10.3390/cancers13133119.
本文引用的文献
1
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.DNA损伤反应通路存在基因突变的胰腺腺癌患者的预后：“了解你的肿瘤”项目的结果
JCO Precis Oncol. 2019 Dec;3:1-10. doi: 10.1200/PO.19.00115.
2
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.索托拉西布治疗晚期实体瘤的 KRAS 抑制作用。
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
3
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.胰腺癌患者对携带抗CD3 x抗表皮生长因子受体双特异性抗体的活化T细胞（EGFR BATs）的临床和免疫反应
Oncoimmunology. 2020 Jun 10;9(1):1773201. doi: 10.1080/2162402X.2020.1773201.
4
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
5
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.DNA 损伤修复作为胰腺癌的治疗靶点：现状与未来展望。
Gut. 2021 Mar;70(3):606-617. doi: 10.1136/gutjnl-2019-319984. Epub 2020 Aug 27.
6
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.BI-3406，一种有效且选择性的 SOS1-KRAS 相互作用抑制剂，通过联合 MEK 抑制作用，对 KRAS 驱动的癌症有效。
Cancer Discov. 2021 Jan;11(1):142-157. doi: 10.1158/2159-8290.CD-20-0142. Epub 2020 Aug 19.
7
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.细胞外囊泡和颗粒生物标志物可定义多种人类癌症。
Cell. 2020 Aug 20;182(4):1044-1061.e18. doi: 10.1016/j.cell.2020.07.009. Epub 2020 Aug 13.
8
Metastatic Pancreatic Cancer: ASCO Guideline Update.转移性胰腺癌：美国临床肿瘤学会（ASCO）指南更新
J Clin Oncol. 2020 Sep 20;38(27):3217-3230. doi: 10.1200/JCO.20.01364. Epub 2020 Aug 5.
9
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.聚乙二醇化重组人尿酸酶与白蛋白结合型紫杉醇加吉西他滨治疗高透明质酸转移性胰腺导管腺癌的随机 III 期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24.
10
Mismatch Repair Pathway, Genome Stability and Cancer.错配修复途径、基因组稳定性与癌症。
Front Mol Biosci. 2020 Jun 26;7:122. doi: 10.3389/fmolb.2020.00122. eCollection 2020.
Zotero 插件